Delivery Order SPE2DB22D2206-SPE2DB24FKC90

Award Date 9/4/24
Potential Completion Date 9/25/24
Potential Value $116K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. The contract has a ceiling value of $34,955.36 and runs through April 2, 2025. The contract is a firm fixed-price, delivery order contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $115,590.40 fixed-price contract is for the supply of OCREVUS 300 mg/10 ml vials, a specialty medication. The contract has a ceiling value of $115,590.40 and an ultimate completion date of September 3, 2024. This order is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has a ceiling value of $24,038.58 and runs through May 5, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $72,115.74, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a prescription medication. The contract is a firm fixed price, non-set-aside award with a completion date of June 25, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $72,115.74, is for the delivery of OCREVUS 300 mg/10 ml vials over a performance period ending on May 20, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999.00, which provides a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a pharmaceutical product, at a firm fixed price. The contract has a ceiling value of $120,192.80 and a completion date of May 20, 2025. This award is not set aside and represents an open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of OCREVUS 300 mg/10 ml vials. The contract has a ceiling value of $115,590.40 and an ultimate completion date of November 21, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $72,115.74 and is for the delivery of OCREVUS 300 mg/10 ml vials, a prescription medication. The contract is a firm fixed-price, non-set-aside arrangement with a performance period ending on May 6, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has a ceiling value of $24,038.58, a firm fixed price pricing type, and a period of performance through February 4, 2025. This is a delivery order contract, not associated with a larger contracting vehicle. The...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of OCREVUS 300 mg/10 ml vials. The contract has a ceiling value of $69,354.24 and a completion date of August 9, 2024. It is a firm fixed-price delivery order contract, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued...
  • SPE2DB22D2206
    Indefinite Delivery Contract
  • SPE2DB22D2206-SPE2DB24FKC90
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a prescription pharmaceutical product. The contract has a value of $115,590.40 and a completion date of September 25, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation. AmerisourceBergen, a major pharmaceutical distributor, has been awarded this contract to provide the specified medication to support federal healthcare programs and facilities, including military treatment facilities and veterans' hospitals. The company holds several Indefinite Delivery Contracts (IDCs) with the DLA and other agencies, valued at up to $999,999,999 and $750,000, respectively, for the supply of a wide range of pharmaceutical and medical products.

Generated 12/4/24, 9:41 AM